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Abstract
Background Oral emergency contraceptives containing levonorgestrel or ulipristal acetate are available without prescrip-
tion and only in pharmacies in Germany since March 2015. Due to this change community pharmacists are responsible for 
evaluating whether the product is appropriate and to educate women on proper use. Objective To measure the utilization of 
emergency contraceptives without a prescription and describe potential concerns and safety issues identified by community 
pharmacists in Germany. Setting The Drug Commission of German Pharmacists’ nationwide network of reference pharma-
cies which includes 860 community pharmacies. Methods Reference community pharmacies were asked to participate in the 
eleven-questions online survey. Respondents were asked to recall their experiences with oral emergency contraceptives in the 
past 3 months. Data were collected between January 8 and February 19, 2018. Main outcome measure The survey focused 
on the utilization of emergency contraceptives without a prescription in Germany, and on the pharmacists’ experiences with 
(potential) problems and concerns regarding safe use. Results In total, 555 community pharmacies (64.5%) participated. 
Overall 38.2% of community pharmacists stated they dispensed six to ten courses of emergency contraceptives within the 
past 3 months. In addition, 54.3% of the pharmacists estimated they dispensed emergency contraceptives exclusively without 
prescription and 35.9% dispensed more than 30% of emergency contraceptives during night-time and emergency services. 
Moreover, 82.8% of pharmacists stated that emergency contraceptives were requested not by the women concerned but a third 
person and 44.3% identified uncertainties in woman’s self-diagnosis. Three out of four pharmacists had concerns about the 
effective and safe use of emergency contraceptives. In situations suggesting sexually transmitted diseases, or suspicion for 
use of force, 59.5% and 55.8% of the pharmacists, respectively, dispensed emergency contraceptives. In cases of acute health 
impairment or chronic disease, or (potentially) relevant drug/drug interaction, the vast majority (91.0% and 90.5%) did not. 
Here, most pharmacists referred to gynecologists. Conclusion Pharmacists had safety concerns when dispensing emergency 
contraceptives. Professional expertise in evaluating the need for oral emergency contraceptives and the proper use is needed.
Keywords Community pharmacy · Emergency contraceptives · Germany · Medication safety · Self-medication · Survey
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Impact of research findings
• Low-threshold access to oral emergency contraceptives 
leads to high proportions of emergency contraception 
dispensing during night-time- and emergency-services, 
as German community pharmacists confirm
• Community pharmacists reveal awareness regarding the 
effective and safe use of oral emergency contraceptives, 
especially for self-medication, and additionally evaluate 
the need to refer women to a gynecologist.
Introduction
Emergency contraceptives (EC) are used to prevent unin-
tended pregnancy after unprotected sex, contraceptive fail-
ure, or coerced sexual intercourse [1–3]. In Germany, oral 
EC containing levonorgestrel (LNG) or ulipristal acetate 
(UPA) are available without a prescription and only in phar-
macies (over-the-counter, OTC) since March 2015. Here, 
sales figures have risen to approx. 808,000 packages in 2017 
(662,000 in 2015), with 90% of the volume accounting for 
EC sales without a prescription [4].
Due to this change in the regulatory status (OTC-
switch), community pharmacists are responsible to ensure 
that women use oral EC appropriately [5–8]. In 2016, the 
German Federal Chamber of Pharmacists (BAK) devel-
oped recommendations, a protocol for consultation, and a 
continuing education program for pharmacists to ensure a 
positive benefit/risk balance when dispensing oral EC with-
out a prescription in German community pharmacies (CPs) 
[9]. The recommendations refer to the existing evidence in 
terms of effectiveness and safety of oral EC. Pharmacists 
are encouraged to refer to the early application of oral EC 
and to evaluate the woman’s individual characteristics e.g., 
age, body weight, or relevant primary and/or concomitant 
diseases [10, 11].
Safety issues, from a pharmacist’s perspective, are criti-
cal to understand potential problems related to the use of 
oral EC. In this context, the Drug Commission of German 
Pharmacists (AMK) represents an independent national 
institution of pharmacovigilance and collects, assesses, 
and evaluates risks of medicinal products, spontaneously 
reported by German pharmacists, as defined by § 63 of the 
German Medicinal Products Act (AMG) [12, 13]. The AMK 
is organized within the ABDA—Federal Union of German 
Associations of Pharmacists, the umbrella organization of 
all pharmacists and more than 90% of German CPs.
To get access to data on safety-related issues in pharmacy 
practice, the AMK established a nationwide network of ref-
erence CPs. The AMK network comprises CPs of various 
sizes, in terms of both, staff and turnover, and geographical 
locations (urban, rural, peripheral and border regions). Ref-
erence CPs are appointed by the 17 State Chambers of Phar-
macists and are distributed throughout Germany. For the 
nomination as a reference CP, several quality criteria apply: 
verification of an established quality management system, 
a high commitment in areas of education and advanced 
vocational training, and affinity for digital correspondence 
(email, Internet).
For this study, AMK reference CPs provided current 
data on oral EC dispensing. In particular, pharmacists were 
requested to report experiences in potential problems and 
safety issues, related to EC self-medication.
Aim of the study
This survey of the AMK reference CPs was conducted to 
provide data on the current practice of oral EC dispensing 
in Germany, with a focus on potential problems and safety 
issues.
Ethics approval
Ethical approval was not required for the present study. No 
personal identifying information was collected and no eth-
ics committee approval was applied. The article does not 
contain any studies with animals performed by any of the 
authors.
Methods
The AMK reference pharmacy network
At the time of the survey, the AMK reference network 
included 860 CPs, that is 4.4% of the 19,748 CPs in Ger-
many [4]. Upon appointment, reference CPs were asked 
to accept the terms of agreement to participate in surveys. 
However, CPs have the option not to participate or not 
responding to selected questions. Available characteristics 
of the AMK reference CPs are provided in Supplementary 
material 1.
Online survey
We developed a survey using the Survey Monkey online tool 
(Dublin, Ireland). The questions were compiled, evaluated, 
and reviewed by the authors until agreement (Supplemen-
tary material 2). On December 20, 2017, all reference CPs 
received an email about the upcoming online-survey pro-
viding the questionnaire. This approach enabled an analysis 
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of the requested information by the CPs. The survey was 
launched on January 8, 2018. An email was sent to all refer-
ence CPs with a brief preamble on the topic of emergency 
contraception, including a link to the eleven-questions-sur-
vey. Reminders were sent on January 31, 2018 and February 
12, 2018. The survey concluded on February 19, 2018. No 
personal identifying information was collected and no ethics 
committee approval was applied.
EC used in the context of this survey equal oral EC avail-
able without a prescription in Germany since March 2015. 
Thus, hereinafter the term EC corresponds exclusively to 
LNG or UPA-containing oral EC.
Domains of interest
Participants were asked to answer in the context of the last 
3 months prior to the survey. The domains of interest com-
prised (1) the characteristics of EC dispensing, including 
night-time and emergency services and prescription versus 
non-prescription ratios, as well as the duration of EC coun-
seling, (2) the reasons for an EC request and the criteria 
determining the use of UPA or LNG, (3) problems related 
to EC dispensing/counseling, and (4) frequency and reasons 
for pharmacists’ concerns in terms of the effective and safe 
use of EC.
Most questions were multiple choice. For some questions, 
multiple answers and/or additional free-text comments were 
allowed. Available free-text answers were analyzed and sum-
marized/categorized according to the content.
Statistical analyses
Descriptive statistics were compiled for each question. The 
data were summarized and analyzed using Microsoft Office 
Excel 2016 (Microsoft, Redmond, WA, USA).
Results
Of 860 reference CPs contacted, 555 participated in the sur-
vey (response rate 64.5%).
Frequency of EC dispensing after OTC‑switch 
and time for counseling
When asked about the dispensing characteristics in CPs 
within the last 3  months, pharmacists declared most 
often (n = 211, 38.2%) to dispense six to ten EC pack-
ages, whereas others dispensed less (≤  5 packages; 
n = 133, 24.1%) or more (11–15 packages; n = 101, 18.3%) 
(Table 1A). Moreover, 300 (54.3%) solely dispensed EC 
for self-medication, and further 167 (30.2%) dispensed EC 
on prescription to a maximum of 5% (Table 1B).
CPs were asked to provide the number of performed 
night-time and emergency services within the past 
3 months, and the estimated proportion of EC dispensing. 
The average amount of night-time and emergency services 
was 5.6 days (median = 4 days, Table 2). In total, 198 CPs 
(35.9%) estimated that more than 30% of EC requests took 
place during night-time and emergency services. In con-
trast, only 47 (8.5%) did not dispense EC during these 
services (Table 1C).
Time needed for appropriate counseling (Table 1D): 313 
pharmacists (56.6%) reported 6–10 min and 181 (32.7%) up 
to 15 min, and even more.
Table 1  Dispensing characteristics of EC
(A) Quantity of EC packages dispensed in CPs within the last 
3  months. Dispensing volumes ranged from 0 to > 20 packages; 
n = 552 CPs responded. (B) Percentage of EC dispensing on prescrip-
tion. Proportions ranged from 0% (no EC on prescription) to > 50%; 
n = 553 CPs responded. (C) EC dispensing during night-time and 
emergency services. Percentages ranged from 0% to > 30%; n = 552 
CPs responded. (D) Average time needed for counseling EC. Dura-
tions were set from ≤ 5 min to > 15 min; n = 553 CPs responded
Respondents (n, %)
(A) Quantity of EC packages dispensed in CPs (n)
 0 1 (0.2)




 > 20 59 (10.7)
(B) Ratio of EC on prescription versus OTC (%)
 0 300 (54.3)




 > 50 4 (0.7)
(C) Ratio of EC dispensing during night-time and emergency 
services (%)
 0 47 (8.5)




 > 30 198 (35.9)
(D) Estimated duration needed for counseling EC (minutes)
 ≤ 5 59 (10.7)
 6–10 313 (56.6)
 11–15 150 (27.1)
 > 15 31 (5.6)
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Reasons for EC request and factors determining 
pharmacists’ selection of UPA or LNG
Reasons for the EC request: most frequently, the follow-
ing statements were given: a busted or broken condom 
(n = 518, 93.5%), a forgotten use of regular contraceptives 
(n = 368, 66.4%), and unprotected sex, but no wish for a 
child (n = 372, 67.2%) (Table 3A). Moreover, 140 (25.3%) 
referred to the woman’s concern, that the effectiveness of the 
regular contraception is limited e.g., due to acute diarrhea.
Using preselected statements, pharmacists informed 
about relevant criteria determining the selection of UPA 
or LNG (Table 3B). Most commonly, the duration between 
the unprotected sexual intercourse and the arrival of the 
woman at the CP was considered to be relevant (n = 335, 
61%). However, 311 (56.7%) generally declared UPA as the 
first-line option, compared to 105 (19.1%) preferring LNG 
within the first 72 h after unprotected sex. Specific requests 
by the women relating to pricing, advertisement, or personal 
advice were also relevant, as 196 (35.7%) responded.
Regarding available free-text comments (n = 35), the 
three most common issues are outlined: for eight pharma-
cists, the estimated date of the woman’s next menstruation is 
relevant, seven considered UPA to be more safe than LNG, 
and six addressed potential drug/drug interactions.
Potential problems when counseling and dispensing 
EC
To evaluate potential problems when counseling and dis-
pensing EC, CPs were asked to confirm selected statements. 
Overall, 434 (82.8%) answered that EC were not requested 
by the woman concerned, but a third person (Table 4A). 
Additionally, 232 (44.3%) confirmed uncertainties in wom-
an’s self-diagnosis. Adherence problems e.g., due to lan-
guage barriers, were stated by 110 (21.0%) and further 43 
(16.1%) detected (potential) medication errors. Additionally, 
101 free text answers were given, of which the two most 
common issues were: 31 pharmacists repeated uncertainties 
in women’s self-diagnosis e.g., due to limited sex education. 
Meanwhile, 23 explicitly reported no problems at all.
Table 2  Number of night-time 
and emergency services (within 
past 3 months)
Data given by CPs were collected as number of days and depicted in a schedule ranging from 0 days (no 
night-time or emergency services) to > 20 days. In total, n = 547 CPs responded
Days (n) 0 1–5 6–10 11–15 16–20  > 20
Respondents (n) 1 350 158 26 8 4
Table 3  Reasons for emergency contraception and criteria to select UPA or LNG
(A) Reasons for EC requests within the last 3 months. CPs were asked to confirm given statements; n = 554 CPs answered. Multiple answers 
were possible. (B) Eligibility criteria for LNG- or UPA-containing EC; n = 549 CPs responded. Multiple answers were possible
Respondents (n, %)
(A) Reasons for requesting EC for self-medication
  Busted or broken condom 518 (93.5)
  Forgotten use of regular contraception 368 (66.4)
  Unprotected sexual intercourse, but no wish for child 372 (67.2)
  Limited effectiveness of regular oral contraception assumed 140 (25.3)
  To have EC in stock 47 (8.5)
  (Potential) embryo-/fetotoxic risk due to medication 3 (0.5)
(B) Pharmacists’ criteria for choosing LNG- or UPA-containing EC
  LNG is more suitable within 72 h 105 (19.1)
  UPA is more suitable 311 (56.7)
  More practical experience exist for LNG 92 (16.8)
  Specific request by the woman relating to pricing, advertisement, or personal advice by family, friends or others 196 (35.7)
  Specific request by the woman due to personal experience and/or medical prescription 116 (21.1)
  Former (potential) occurrence of side effects and/or intolerance 33 (6)
  Interval between unprotected sexual intercourse or contraceptive failure and arrival of the women at pharmacy 335 (61.0)
  The woman is in lactation period 83 (15.1)
  Availability of LNG- or UPA-containing EC at pharmacy 122 (22.2)
  Purchasing conditions of the pharmacy 7 (1.3)
1503International Journal of Clinical Pharmacy (2019) 41:1499–1506 
1 3
Pharmacists also estimated how often they had concerns 
about the effective and safe use of EC. Almost three out of 
four had concerns at least once within the past 3 months 
(Table 4B). Moreover, eight (1.5%) were concerned in more 
than 50% of the cases. Only 147 (26.6%) had no concerns.
Dispensing EC (or not) and additional advice 
for women
Three out of four pharmacists had concerns whether the use 
of EC is appropriate, at least once within the past 3 months. 
Thus, the survey additionally asked for the reasons, why 
these concerns were raised and listed 13 predefined sce-
narios. If the scenario was confirmed, pharmacists were 
requested to state, whether in this specific situation EC 
was dispensed (or not) and if the woman was referred to a 
gynecologist. In fact, each of the given statements were veri-
fied by a different number of CPs, with an overall trend to 
restrict EC dispensing, and to refer the woman to a gynecol-
ogist (Table 5).
Most frequently (n = 212), the pharmacists stated that 
the need for EC was questionable e.g., when the usual 
oral contraceptive was forgotten and the sexual intercourse 
occurred less than 12 h ago. Herein, 114 (43.7%) still dis-
pensed EC and overall 90 (34.5%) referred the woman to a 
gynecologist. A request to buy EC in stock was confirmed 
by 173 CPs. Thus, 152 (87.9%) did not dispense EC, and 
52 of them referred the woman to a gynecologist. Further 
128 pharmacists stated that women requested EC later 
than 5 days after unprotected sex, whereupon 96 (75.0%) 
did not dispense EC and overall 108 (84.3%) referred the 
woman to a gynecologist. In case an existing pregnancy 
was suspected (n = 104), 92 (88.5%) did not dispense EC, 
of whom 85 (81.7%) referred the woman to a gynecolo-
gist. When a risk of sexually transmitted diseases was sug-
gested, 25 of 42 pharmacists (59.5%) dispensed EC and 
39 referred the woman to a gynecologist (92.9%). If use of 
force was suspected (n = 43), 24 (55.8%) dispensed EC and 
40 (93.0%) referred the woman to a gynecologist.
For other scenarios, such as the repeated use within 
the same menstrual cycle (n = 113), EC request by girls 
younger than 14 years without parental informed consent 
(n = 89), acute health problems or chronic diseases (n = 88) 
or potential clinically relevant drug/drug interactions 
(n = 74), pharmacists commonly denied EC dispensing 
and referred the woman to a gynecologist. In situations of 
sustained vomiting/diarrhea (n = 61), obesity (n = 52), or 
in case the pharmacist declared ethical/religious reserva-
tions regarding the use of EC, the proportion of dispensing 
versus non-dispensing EC was similar.
Overall, only a few pharmacists dispensed EC without 
additional referral to gynecologists.
Discussion
Community pharmacists are responsible to educate women 
in the proper use of EC. According to the summary of prod-
uct characteristics (SmPCs), LNG can be used within 3 days 
and UPA within 5 days after unprotected sex or contracep-
tive failure [14]. High proportions of EC dispensing during 
Table 4  Problems and concerns 
when dispensing EC
(A) Problems when dispensing EC without prescription within the past 3 months. CPs were asked to con-
firm given statements; n = 524 CPs responded. Multiple answers were possible. (B) Estimated frequency 
of concerns when counseling/dispensing EC. Ratio ranged from 0% (no concerns) to > 50%; n = 553 CPs 
responded
Respondents (n, %)
(A) Problems when counseling/dispensing EC
  (Former) side effects after use of oral EC were reported 18 (3.4)
  EC was not requested by the woman concerned but the respective man or a third 
person
434 (82.2)
  (Potential) medication errors when administering EC were detected 43 (8.2)
  Compliance problems e.g., due to language barriers 110 (21.0)
  Uncertainties in self-diagnosis of the woman 232 (44.3)
  Forensic relevant evidence e.g., suspicion of use of force 11 (2.1)
(B) Frequency of pharmacist’s concerns (%)
  0 147 (26.6)




  > 50 8 (1.5)
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night-time and emergency services indicates that women are 
aware to use EC early. Indeed, the vast majority of phar-
macists confirmed that women ask for EC within 12 h or 
3 days (Supplementary material 3). However, the survey also 
revealed, that pharmacists had concerns about the effective 
and safe use of EC, at least once within the past 3 months, 
because women requested EC later than 5 days. Thus, evalu-
ating the appropriate use of EC remains highly important in 
everyday pharmacy practice.
However, it is still impossible to confirm that low-thresh-
old availability alone reduces the number of pregnancy ter-
minations [15, 16]. At least in the Federal States of Germany 
with relatively high rates of EC use, there is a trend towards 
fewer terminations [17]. Moreover, a need for re-evaluating 
or establishing official guidelines for dispensing practices 
was indicated, when identifying differences in gynecolo-
gists’ and pharmacists’ views on EC [18–20]. Thus, the BAK 
protocol for consultation, and a continuing education pro-
gram for pharmacists were developed [9, 21]. The protocol 
provides a checklist, which allows CPs to document each 
individual EC request.
Women ask for EC either due to contraceptive failure, 
the forgotten use of a regular contraceptive, or unprotected 
sex but no wish for a child, as the survey revealed. It is 
unknown, for the latter, whether women are aware of the 
risk for unintended pregnancy or misinformed about birth 
control. Possible considerations are manifold and include 
knowledge about (emergency) contraception [7], use of EC 
as a regular contraception [22] or rely on “fertility aware-
ness” or “pregnancy prevention” apps [23, 24]. Moreover, 
the survey did not explicitly list a coerced sexual inter-
course, but 43 CPs confirmed a suspicion of use of force 
or sexual traumatization. This request is an integral part of 
the BAK protocol to facilitate a structured EC counseling 
[9, 21].
The time lag between unprotected sexual intercourse 
and the consultation at the CP is relevant when selecting 
UPA or LNG, as most pharmacists declared. Nevertheless, 
a clear tendency towards UPA was noticeable. The favor 
for UPA might reflect the differences in the applicability 
(3 vs. 5 days), but it could also be speculated that UPA is 
generally considered an advance in EC [25]. Indeed, the 
recent Cochrane systematic review declared UPA to be more 
effective than LNG [26]. Furthermore, the use of EC is also 
a matter of safety. LNG and UPA are suggested to have a 
similar safety profile, with serious adverse drug reactions 
essentially unknown [27–29]. But as LNG is approved as 
OTC much longer, more is known about its adverse effects 
through pharmacovigilance activities [30].
Table 5  Pharmacists’ decision whether to dispense EC, or not, and/or refer the woman to a gynecologist
Dispensing EC No Yes
Sum (n)Referral to a gynecologist Yes No Yes No
Respondents
Scenario n, (%) n, (%)
Request for EC in stock 
(no acute emergency contraception). 52 (30.1) 100 (57.8) 13 (7.5) 8 (4.6) 173
Questionable indication for EC 
(e.g usual oral contraception was forgotten and unprotected 
sex dates back less than 12h).
84 (32.2) 63 (24.1) 87 (33.3) 27 (10.3) 261
Unprotected sexual intercourse or contraception failure was 
more than 120h (5 days) ago. 78 (60.9) 18 (14.1) 30 (23.4) 2 (1.6) 128
Present acute health problems or chronic diseases (e.g. 
malabsorption syndrome, severe hepatic dysfunction, previous 
tubal inflammation).
71 (80.7) 9 (10.2) 7 (8.0) 1 (1.1) 88
(Potential) clinically relevant drug/drug interactions suspected
due to concurrent medication (e.g. cytochrome (CYP) 3A4-
inducers like rifampicin, barbiturates, phenytoin).
64 (86.5) 3 (4.1) 6 (8.1) 1 (1.4) 74
Sustained vomiting/diarrhea. 30 (49.2) 5 (8.2) 23 (37.7) 3 (4.9) 61
Repeated use within the same menstrual cycle. 76 (67.6) 10 (8.9) 25 (22.1) 2 (1.8) 113
Suspicion of an existing pregnancy. 85 (81.7) 7 (6.7) 10 (9.6) 2 (1.9) 104
Signs suggesting a risk of sexually transmitted diseases (e.g. 
syphilis, human papillomavirus (HPV) etc.). 15 (35.7) 2 (4.8) 24 (57.1) 1 (2.4) 42
Girls younger than 14 years without informed consent of a 
parent or legal guardian. 73 (82.0) 10 (11.2) 4 (4.5) 2 (2.3) 89
(Massive) obesity of the woman. 25 (48.1) 3 (5.8) 22 (42.3) 2 (3.9) 52
Personal ethical/religious reservations regarding EC. 11 (44.0) 3 (12.0) 3 (12.0) 8 (32.0) 25
Suspicion of use of force/ sexual traumatization. 17 (39.5) 2 (4.7) 23 (53.5) 1 (2.3) 43
Potential reasons for concerns regarding the effective and safe use of EC. CPs were asked to confirm given statements as reasons for concerns, 
and to report whether EC were dispensed (or not) and if the woman was referred to a gynecologist; n = 398 CPs responded. Multiple answers 
were possible
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According to the sales volume in Germany at the time 
of the survey, a CP dispensed on average 10.1 EC pack-
ages (9.2 packages without a prescription) within 3 months. 
Noteworthy, the frequency of EC dispensing, reported by 
the reference CPs, reveal striking consistency with these fig-
ures. The rise in OTC-use was also confirmed. Moreover, 
EC counseling is present and (relatively) time-consuming 
[31]. Pharmacists frequently advise the recommended use 
of EC and refer the woman to a gynecologist to maintain 
medication safety. They also respect duties of care obliga-
tions when dispensing to minors. The SmPCs do not specify 
age limits, but the BAK guidelines recommend not to dis-
pense EC to girls under 14 without a prescription or the 
consent of a parent or legal guardian [9, 32]. However, it 
remains arguable if the overall restrictive EC dispensing 
due to pharmacists’ concerns about the safe use of EC may 
constitutes an (unnecessary) barrier for women who require 
early and effective pregnancy prevention [33]. As indicated, 
EC have an adequate safety profile, and the benefit outweigh 
the risk [34–36]. Thus, the BAK recommendations advice 
not to dispense EC for self-medication exclusively in situ-
ations where the unprotected sexual intercourse was more 
than 5 days ago, a pregnancy is suspected, or the use of EC 
is contraindicated [9, 21].
However, scientific caution is advised when interpreting 
the individual circumstances of EC dispensing restrictions. 
In real world situations, different concomitant attributes may 
emerge e.g., an obese woman (BMI ≥ 35) with acute health 
problems and a request to buy EC in stock. Here, pharma-
cists have to decide individually whether to dispense EC or 
not. Moreover, some criteria addressed in the survey, e.g. the 
repeated administration of EC within a menstrual cycle, are 
not concordant for LNG and UPA. The repeated use is not 
advisable for LNG, because of the possibility of disturbance 
of the cycle. However, this safety advice is missing in the 
SmPC of UPA-containing EC.
Limitations
We do not know whether the data provided are based on 
pharmacy records documenting every EC request [9] or from 
recall; the latter leading to more subjective answers. Some 
aspects may have led to misinterpretation e.g., the given 
scenarios which did not necessarily depict real world situa-
tions. For some predefined statements, decision making by 
pharmacists might depend on the type of EC (UPA or LNG), 
which could not be considered in the multiple-choice setup 
of the survey. In addition, the risk of misclassification and 
imprecision is increased when one participant answered on 
behalf of several pharmacists, who likewise dispense EC in 
everyday pharmacy practice. To overcome these restrictions, 
the survey was conducted over a month long, allowing the 
participating CPs to comprehensively discuss and analyze 
the requested information internally. Finally, the AMK ref-
erence pharmacies are probably not representative of the 
larger population of German CPs. Notwithstanding, refer-
ence CPs revealed consistency with the nationwide EC sales 
figures and the prescription versus non-prescription dispens-
ing ratios. Compared to other surveys, the response rate of 
64.5% and the number of participating CPs were high [7, 
20, 30, 37].
Conclusion
The reference community pharmacies of the Drug Commis-
sion of German Pharmacists confirm the substantial rise in 
OTC sales figures for emergency contraceptives in Germany. 
Pharmacists give advice for the correct and safe use and refer 
the women to gynecologists, in case of safety concerns. The 
professional expertise ensures a positive benefit/risk balance 
for emergency contraceptive dispensing and use.
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